Tammie Ford McMillan had planned to use her alternative on the back of T-shirts which would be personalised on the front with ...

Is the GYG valuation too spicy? The post Guzman Y Gomez shares: Overvalued or still a buy? appeared first on The Motley Fool ...

An Initial Public Offering (IPO) is the process through which a private company offers its shares to the public for the first time, becoming publicly traded on a stock exchange. It enables ...

Use our IPO calendar to view upcoming IPOs and new IPOs. Assess recent IPO prices and public offering value. Keep track of the latest IPO stocks, news and Initial Public Offering (IPO) analysis.

Standard Glass Lining Technology's IPO was oversubscribed within an hour of opening, driven by strong retail and non-institutional investor interest. The company plans to use proceeds for capital ...

"In this era of 'reformasi'? Will we get to pass if we wear a Bersih shirt?" Nooryana Najwa Najib asked in an Instagram story on Sunday (Jan 5). Police had previously set up roadblocks to prevent ...

It also reflects a shift in investor appetite after many were burnt by bad bets on lossmaking start-ups during the pandemic-era IPO rush. “These are companies that generally speaking are larger ...

The owners of Shawbrook Group, the mid-sized British lender, are drawing up plans to kickstart London's moribund listings arena with a stock market flotation, valuing it at more than £2bn.

January 03, 2025 / 14:06 IST Indo Farm Equipment IPO Allotment Status Live: Who are the book-running lead manager and registrar for Indo Farm IPO? Aryaman Financial Services serves as the book ...

Standard Glass Lining IPO: The initial public offering (IPO) of engineering equipment manufacturer Standard Glass Lining Technology Ltd is set to hit Dalal Street next week as the company plans to ...

Indofarm IPO 2025: IPO is priced between Rs 204 to Rs 215 per share (Image: Canva) Indo Farm Equipment IPO, with a price band set between the range of Rs 204 to Rs 215, ran its public issue from ...

Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug candidates and the lives of people who work in biotech. Evaluate analysts ...